Dawnrays Pharmaceutical (Holdings) Ltd

Dawnrays Pharmaceutical (Holdings) Ltd

Health CarePharmaceuticals and Biotechnology
  • Price (HKD)1.31
  • Today's Change0.00 / 0.00%
  • Shares traded28.00k
  • 1 Year change-6.43%
  • Beta0.5095
Data delayed at least 15 minutes, as of Mar 28 2023 02:48 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Dawnrays Pharmaceutical (Holdings) Limited is an investment holding company principally engaged in the development, manufacture and sale of non-patented pharmaceutical medicines. The products include intermediate pharmaceutical, bulk medicines and finished drugs. The Company operates its business through two segments. The Intermediates and Bulk Medicines segment is engaged in the manufacture and sale of intermediates and bulk medicines. The Finished Drugs segment is engaged in the manufacture and sale of finished drugs, including antibiotics finished drugs and non-antibiotics finished drugs.

  • Revenue in HKD (TTM)1.36bn
  • Net income in HKD418.08m
  • Incorporated2002
  • Employees1.06k
  • Location
    Dawnrays Pharmaceutical (Holdings) LtdUnits 3001-02, 30/F, CNT Tower, Wanchai Hong KongHKG
  • Phone+852 21119708
  • Fax+852 21119870
  • Websitehttp://www.dawnrays.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Transcenta Holding Limited52.16m-1.06bn1.07bn321.00--0.5513--20.45-2.40-2.400.11854.550.01941.654.56143,702.30-39.61---48.08--17.48---2,040.65--2.63-47.970.1908---37.96---441.82------
Genor Biopharma Holdings Ltd3.40m-1.00bn1.15bn452.00--0.4701--337.37-2.01-2.010.00684.830.0010.01750.0295,316.83-30.50---33.43--73.38---29,412.99--8.33--0.0252---100.00--71.42------
TOT Biopharm International Co Ltd270.76m-186.41m1.38bn355.00--2.90--5.08-0.3241-0.32410.47070.6140.32541.655.40803,448.60-22.41---34.33--73.14---68.85--0.8533-14.000.4296--239.36--9.46------
JW (Cayman) Therapeutics Co Ltd111.44m-979.49m1.53bn589.00--0.51--13.72-2.41-2.410.27437.290.03043.112.83208,679.90-26.67---28.28--33.24---878.98--9.74-10.520.0545------57.79------
Hbm Holdings Ltd233.33m-1.17bn1.69bn365.00--1.33--7.24-1.60-1.600.3181.660.0998--25.77606,055.30-50.15---57.13--99.31---502.40------0.2826---69.46--53.52------
Jacobson Pharma Corporation Ltd1.66bn233.82m1.74bn1.80k7.380.67763.961.050.12190.12190.86721.330.33612.805.95957,651.505.104.966.656.8841.3941.4115.1713.743.0910.160.341432.4610.354.902.28-0.186-7.1112.02
Abbisko Cayman Ltd0.00-570.51m1.88bn192.00--0.6963-----0.9482-0.94820.003.850.00-------19.27---19.97--------------0.019---100.00--72.62------
Golden Throat Holdings Group Co Ltd874.14m187.48m1.91bn937.0010.,909.409.078.5712.6412.0269.6972.6821.4518.782.38159.040.180656.2526.831.3321.8012.7644.8222.25
SinoMab Bioscience Ltd0.00-327.11m1.91bn296.00--3.26-----0.3298-0.32980.000.56680.00-------27.72-25.55-32.21-28.89-------4,070.71---6.120.4121---100.00--1.40------
Dawnrays Pharmaceutical Holdings Ltd1.36bn418.08m2.01bn1.06k4.830.70554.121.480.27730.27730.90131.900.38392.397.001,275,490.0011.7211.4513.9513.8359.2658.7130.5329.602.3120.120.010542.6813.757.1733.586.1465.212.29
Antengene Corporation Ltd95.23m-652.68m2.05bn383.00--0.7943--21.54-1.05-1.050.15323.830.03072.901.68289,447.20-21.02---22.36--83.94---685.39--11.13--0.0156------77.62------
Zhaoke Ophthalmology Ltd0.00-348.97m2.06bn268.00--0.72-----0.6442-0.64420.005.250.00----0.00-11.24---11.70-------------127.180.0247-------192.96------
Essex Bio-Technology Ltd1.32bn225.41m2.13bn1.42k9.751.237.991.620.38270.38272.203.030.47271.422.34--8.0912.3210.4216.1390.2684.2917.1120.722.02--0.220515.58-19.547.93-34.856.14--5.39
Mabpharm Ltd35.09m-303.20m2.23bn389.00--3.94--63.47-0.0735-0.07350.00850.13710.03180.18753.9872,500.48-27.48---35.08--63.71---864.06--0.6451-32.370.205-------58.01------
Clover Biopharmaceuticals Ltd0.00-6.72bn2.50bn814.00--11.03-----12.92-12.920.000.175------0.00----------------1.29-0.78570.3124-------559.03------
Immunotech Biopharm Ltd0.00-399.74m2.50bn267.00--3.17-----0.7768-0.77680.001.530.00----0.00-33.66---37.53----------1.49-18.730.1291------19.32------
Data as of Mar 28 2023. Currency figures normalised to Dawnrays Pharmaceutical (Holdings) Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

10.69%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 30 Sep 202191.68m6.12%
UBS Asset Management (Hong Kong) Ltd.as of 31 Aug 202237.04m2.47%
Dimensional Fund Advisors LPas of 02 Mar 202313.29m0.89%
Fidelity Investments Canada ULCas of 31 Jan 202311.01m0.73%
CATAM Asset Management AGas of 31 Mar 20213.23m0.22%
FIAM LLCas of 31 Jan 20232.35m0.16%
Dimensional Fund Advisors Ltd.as of 31 May 2022707.89k0.05%
LGT Capital Partners AG (Investment Management)as of 30 Nov 2021440.00k0.03%
Acadian Asset Management LLCas of 31 Jan 2023263.95k0.02%
FIL Investments Internationalas of 30 Jun 2022142.00k0.01%
More ▼
Data from 31 Dec 2022 - 16 Mar 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.